Interleukin-1β promotes oligodendrocyte death through glutamate excitotoxicity

Annals of Neurology

Volumn 53, Issue 5, 2003, Pages 588-595

  Takahashi, Jennifer L ^a   Giuliani, Fabrizio ^a   Power, Christopher ^a   Imai, Yoshinori ^b   Yong, V Wee ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR ANTAGONIST; CYTOKINE; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; INTERLEUKIN 1BETA; KAINIC ACID RECEPTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA; 2,3 DIOXO 6 NITRO 7 SULFAMOYLBENZO(F)QUINOXALINE; 2,3-DIOXO-6-NITRO-7-SULFAMOYLBENZO(F)QUINOXALINE; AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; INTERLEUKIN 1; KAINIC ACID RECEPTOR; QUINOXALINE DERIVATIVE;

AMINO ACID METABOLISM; ANIMAL CELL; APOPTOSIS; ARTICLE; ASTROCYTE; CELL ACTIVATION; CELL CULTURE; CELL DEATH; CELL DESTRUCTION; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; MICROGLIA; MIXED CELL CULTURE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; CEREBROSPINAL FLUID; CULTURE TECHNIQUE; DRUG ANTAGONISM; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NICK END LABELING; PATHOLOGY; PHYSIOLOGY;

APOPTOSIS; CELL CULTURE TECHNIQUES; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTERLEUKIN-1; MICROGLIA; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; QUINOXALINES; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038416100     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10519     Document Type: Article

References (44)

1. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
2. Casaccia-Bonnefil P. Cell death in the oligodendrocyte lineage: a molecular perspective of life/death decisions in the development and disease. Glia 2000;29:124-135.
3. Matute C, Sanchez-Gomez MV, Martnez-Millan L, Miledi R. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc Natl Acad Sci USA 1997;94:8830-8835.
4. McDonald JW, Althomsons SP, Hyrc KL, et al. Oligodendrocytes from forebrain are highly vulnernable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med 1998;4:291-297.
5. Sanchez-Gomez MV, Mature C. AMPA and kainate receptors each mediate excitotoxicity in oligodendroglial cultures. Neurobiol Dis 1999;6:475-485.
6. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000;6:62-66.
7. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000;6:67-70.
8. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001;50:169-180.
9. Stover JF, Pleines UE, Morganti-Kossmann MC, et al. Neurotransmitters in the cerebrospinal fluid reflect pathological activity. Eur J Clin Invest 1997;27:1038-1043.
10. Prineas JW, Kwon EE, Cho ES, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001;50:646-657.
11. Sriram S, Rodriguez M. Indictment of the microglia as the villain in multiple sclerosis. Neurology. 1997;48:464-470.
12. Vecil GG, Larsen PH, Herx LM, et al. Interleukin-1 is a key regulator of matrix metalloproteinase-9 in human neurons in culture and following mouse brain trauma in vivo. J Neurosci Res 2000;61:212-224.
13. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001;2:501-510.
14. Baranzini SE, Elfstrom C, Chang SY, et al., Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J Immunol 2000;165:6576-6582.
15. Brogi A, Strazza M, Melli M, Costantino-Ceccarini E. Induction of intracellular ceramide by interleukin-1β in oligodendrocytes. J Cell Biochem 1997;66:532-541.
16. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1998;23:339-346
17. Louis JC, Magal E, Takayama S, Varon S. CNTF protection of oligodendrocytes against natural and tumor necrosis factorinduced death. Science 1993;259:689-692.
18. D'Souza S, Alinauskas K, McCrea E, et al. Differential susceptibility of human CNS-derived cell populations to TNFdependent and independent immune-mediated injury. J Neurosci 1995;15:7293-7300.
19. Bourros T, Croze E, Yong VW. Interferon-beta is a potent promoter of nerve growth factor production by astrocytes. J Neurochem 1997;69:939-946.
20. Corley SM, Ladiwala U, Besson A, Yong VW. Astrocytes attenuate oligodendrocyte death in vitro through an α6 integrinlaminin-dependent mechanism. Glia 2001;36:281-294.
21. Ito D, Imai Y, Ohsawa K, et al. Microglia-specific localization of a novel calcium binding protein, Iba1. Mol Brain Res 1998;57:1-9.
22. Ye ZC, Sontheimer H. Cytokine modulation of glial glutamate uptake: a possible involvement of nitric oxide. Neuroreport 1996;7:2181-2185.
23. Hu S, Sheng, WS, Ehrlich LC, et al. Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation 2000;7:153-159.
24. Patneau DK, Wright PW, Winters C, et al. Glial cells of the oligodendrocyte lineage express both kainate- and AMPApreferring subtypes of glutamate receptor. Neuron 1994;12:357-371.
25. Yoshioka A, Hardy M, Younkin DP, et al. α-Amino-3hydroxy-5-methyl-4-isoaxazolepropionate (AMPA) receptors mediate excitotoxicity in the oligodendroglial lineage. J Neurochem 1995;64:2442-2448.
26. Karp CL, can Boxel-Dezaire AH, Byrnes AA, Nagelkerken L. Interferon-beta in multiple sclerosis: altering the balance of interleukin-12 and interleukin-10? Curr Opin Neurol 2001;14:361-368.
27. Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiple sclerosis: current pathophysiological concepts. Lab Invest 2001;81:263-281
28. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002;3:291-301.
29. Brosnan CF, Cannella B, Battistini L, et al. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1665;45(suppl):S16-S21.
30. Woodroofe MN, Cuzner ML. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by nonradioactive in situ hybridization. Cytokine 1993;5:583-588.
31. Pender MP, Nguyen KB, McCombe PA, Kerr JFR. Apoptosis in the nervous system in experimental allergic encephalomyelitis. J Neurol Sci 1991;104:81-87.
32. Ozawa K, Suchanek G, Breitschopf H, et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994;117:1311-1322.
33. Bonetti B, Raine CS. Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol 1997;42:74-84.
34. Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996;16:675-686.
35. Ohgoh M, Hanada T, Smith T, et al. Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis. J Neuroimmunol 2002;125:170-178.
36. Anderson CM, Swanson RA. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 2000;32:1-14.
37. Fine SM, Angel RA, Perry SW, et al. Tumor necrosis factor a inhibits glutamate uptake by primary human astrocytes. J Biol Chem 1996;271:15303-15306.
38. Bezzi P, Domercq M, Brambilla L, et al. CXCR4-activated astrocyte glutamate release via TNFα: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001;4:702-710.
39. Jacobs CA, Baker PE, Roux ER, et al. Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. J Immunol 1991;146:2983-2989.
40. Chabot S, Yong VW. Microglia in the CNS. In: Walz W, ed. Neuronal microenvironment. Totowa, NJ: Humana Press, 2002:379-399.
41. Yrjanheikki J, Keinanen R, Pellikka M, et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998;95:15769-15774.
42. Tikka T, Fiebich BL, Goldsteins G, et al. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001;21:2580-2588.
43. Brundula V, Rewcastle B, Metz L, et al. Targeting leukocyte MMPs and transmigration: minocycline as a novel therapeutic for multiple sclerosis. Brain 2002;125:1297-1308.
44. Popovic N, Schubart A, Goeta BD, et al. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002;51:215-223.